Lyell Immunopharma (LYEL) Change in Cash (2020 - 2026)
Lyell Immunopharma recorded quarterly Change in Cash of $30.6 million in Q1 2026, up 148.25% quarter-over-quarter from -$63.4 million in Q4 2025, and up 107.69% year-over-year from $14.7 million in Q1 2025.
Lyell Immunopharma's Change in Cash history runs 7 years deep, the most recent figure standing at $30.6 million for Q1 2026.
- In Q1 2026, Change in Cash rose 107.69% year-over-year to $30.6 million; the TTM figure through Mar 2026 stood at -$29.7 million (down 656.63% YoY), while the FY2025 annual figure was -$45.5 million, down 17.8% from the prior year.
- Change in Cash came in at $30.6 million for Q1 2026 at Lyell Immunopharma, up from -$63.4 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $114.9 million in Q2 2023 to a low of -$140.6 million in Q4 2023.
- A 5-year average of -$11.9 million and a median of -$14.1 million in 2023 frame the typical range for Change in Cash.
- On a YoY basis, Change in Cash climbed as much as 781.89% in 2023 and fell as far as 2040.45% in 2023.
- Lyell Immunopharma's Change in Cash stood at $7.2 million in 2022, then tumbled by 2040.45% to -$140.6 million in 2023, then soared by 104.77% to $6.7 million in 2024, then tumbled by 1046.18% to -$63.4 million in 2025, then surged by 148.25% to $30.6 million in 2026.
- According to Business Quant data, Change in Cash over the past three periods registered $30.6 million, -$63.4 million, and $24.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 623.00 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 417.10 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -153.10 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 53.61 Mn |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | 30.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.59 Mn |
| Dec 31, 2025 | -63.39 Mn |
| Sep 30, 2025 | 24.77 Mn |
| Jun 30, 2025 | -21.63 Mn |
| Mar 31, 2025 | 14.73 Mn |
| Dec 31, 2024 | 6.70 Mn |
| Sep 30, 2024 | -33.12 Mn |
| Jun 30, 2024 | 7.78 Mn |
| Mar 31, 2024 | -20.00 Mn |
| Dec 31, 2023 | -140.57 Mn |
| Sep 30, 2023 | 61.84 Mn |
| Jun 30, 2023 | 114.95 Mn |
| Mar 31, 2023 | -14.13 Mn |
| Dec 31, 2022 | 7.24 Mn |
| Sep 30, 2022 | -89.43 Mn |
| Jun 30, 2022 | -16.86 Mn |
| Mar 31, 2022 | -71.42 Mn |
| Dec 31, 2021 | -99.68 Mn |
| Sep 30, 2021 | -170.94 Mn |
| Jun 30, 2021 | 320.07 Mn |
| Mar 31, 2021 | 103.96 Mn |
| Dec 31, 2020 | 5.99 Mn |
| Sep 30, 2020 | -111.54 Mn |